COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

Начало・Списък с акции・CSL Ltd

CSL Ltd

Затворен

Сектор

303.69 0.59

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

303.19

Максимум

304.27

Ключови измерители
By Trading Economics
Приходи	1.9B
Продажби	8.1B
EPS	4.159
Марж на печалбата	23.606

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+6.31 upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-686M 148B
Предишно отваряне	303.1
Предишно затваряне	303.69

Настроения в новините

By Acuity

37%

63%

92 / 382 Класиране в Industrials

CSL Ltd Графика

Свързани новини

12.08.2024 г., 23:23 ч. UTC

Печалби

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12.08.2024 г., 22:49 ч. UTC

Печалби

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

12.02.2024 г., 22:16 ч. UTC

Печалби

CSL Says 1st Half Profit Rises, Boosts Dividend -- Update

12.02.2024 г., 22:00 ч. UTC

Печалби

CSL Says 1st Half Profit Rises, Boosts Dividend

13.08.2024 г., 00:33 ч. UTC

Пазарно говорене

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12.08.2024 г., 22:34 ч. UTC

Печалби

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12.08.2024 г., 22:18 ч. UTC

Печалби

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12.08.2024 г., 22:18 ч. UTC

Печалби

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12.08.2024 г., 22:17 ч. UTC

Печалби

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12.08.2024 г., 22:16 ч. UTC

Печалби

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12.08.2024 г., 22:15 ч. UTC

Печалби

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12.08.2024 г., 22:14 ч. UTC

Печалби

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12.08.2024 г., 22:13 ч. UTC

Печалби

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12.08.2024 г., 22:13 ч. UTC

Печалби

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12.08.2024 г., 22:11 ч. UTC

Печалби

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12.08.2024 г., 22:10 ч. UTC

Печалби

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12.08.2024 г., 22:09 ч. UTC

Печалби

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12.08.2024 г., 22:08 ч. UTC

Печалби

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12.08.2024 г., 22:07 ч. UTC

Печалби

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

12.08.2024 г., 22:07 ч. UTC

Печалби

CSL Final Dividend US$1.45/Share

13.02.2024 г., 01:50 ч. UTC

Пазарно говорене

Печалби

CSL Still Confident on Long-Term Value at Vifor Business -- Market Talk

13.02.2024 г., 00:39 ч. UTC

Пазарно говорене

Печалби

UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

12.02.2024 г., 22:01 ч. UTC

Печалби

CSL Says 1H Profit Rises, Boosts Dividend -- Update

12.02.2024 г., 21:45 ч. UTC

Топ новини

Печалби

CSL Says 1H Profit Rises, Boosts Dividend

12.02.2024 г., 21:35 ч. UTC

Печалби

CSL Says 1H Result Driven by CSL Behring Unit, Especially Immunoglobulins

12.02.2024 г., 21:33 ч. UTC

Печалби

CSL Anticipates Loss in 2H for Flu-Vaccine Unit Seqirus Due to Seasonality of Business

12.02.2024 г., 21:33 ч. UTC

Печалби

CSL Says FY 2024 Underlying Profit Growth Expected 13%-17% on-Year

12.02.2024 г., 21:32 ч. UTC

Печалби

CSL Says Underlying Profit Expected in Range of US$2.9-US$3.0 Bln at Constant Currency

12.02.2024 г., 21:31 ч. UTC

Печалби

CSL Reaffirms Previous Guidance

12.02.2024 г., 21:30 ч. UTC

Печалби

CSL 1H Underlying Profit Up 13% on Constant Currency Basis

Сравнение с други в отрасъла

Ценова промяна

CSL Ltd Прогноза

Ценова цел

By TipRanks

6.31% нагоре

12-месечна прогноза

Среден 323.182 AUD 6.31%

Висок 352 AUD

Нисък 278 AUD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за CSL Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на CSL Ltd през последните 3 месеца.

Настроение

By Acuity

92 / 382 Класиране в

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно CSL Ltd

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.